Empagliflozin - Heart failure
You are here : Home > Formulary Search > Empagliflozin - Heart failure
Status 1
- Tablets
Documentation
PAD Profile
Dapagliflozin is the preferred SGLT-2 for heart failure.
Committee Recommendations (3)
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a change in traffic light status for dapagliflozin and empagliflozin for the treatment of symptomatic chronic heart failure.
A GREEN traffic light status was agreed for dapagliflozin and empagliflozin
Dapagliflozin is the preferred SGLT2 inhibitor based on a decision made at the APC in September 2025.
NICE CG106: Chronic heart failure in adults: diagnosis and management has been updated to remove the recommendation that GPs should only initiate under specialist advice.
CKS have updated their Chronic Heart Failure guidelines.
NICE have also produced visual summaries to support prescribers
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed that dapagliflozin will be the preferred SGLT-2 inhibitor in type 2 diabetes, Chronic Kidney Disease and Heart Failure.
The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.
Other Indications
Below are listed other indications that Empagliflozin is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Heart failure.
- Acetazolamide
- Bisoprolol fumarate
- Candesartan cilexetil
- Captopril
- Carvedilol
- Co-amilozide (Amiloride hydrochloride/hydrochlorot
- Dapagliflozin
- Digoxin
- Enalapril maleate
- Enoximone
- Eplerenone
- Hydralazine hydrochloride
- Ivabradine
- Levosimendan
- Lisinopril
- Losartan potassium
- Metolazone
- Milrinone lactate
- Nebivolol
- Perindopril erbumine
- Potassium canrenoate
- Prazosin hydrochloride
- Ramipril
- Sacubitril/valsartan
- Spironolactone
- Valsartan